Therefore, we aimed to develop a triple FXR/PPARα/δ modulator with moderate activation efficacy to unite the anti-NASH activities of the three transcription factors while avoiding potential mechanism-based side effects. Here, PPARA is linked to metabolic dysfunction-associated steatohepatitis.